EUPRAXIA PHARMACEUTICALS INC. Deferred Income Tax Expense (Benefit)
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-13
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 40-F · filed 2026-03-13 |
| 2024-12-31 | $0.00 40-F · filed 2026-03-13 |
| 2023-12-31 | $0.00 40-F · filed 2025-03-20 |
| 2022-12-31 | $0.00 40-F · filed 2024-04-01 |